ECSP22085835A - Moléculas de fijación para el tratamiento de cáncer - Google Patents
Moléculas de fijación para el tratamiento de cáncerInfo
- Publication number
- ECSP22085835A ECSP22085835A ECSENADI202285835A ECDI202285835A ECSP22085835A EC SP22085835 A ECSP22085835 A EC SP22085835A EC SENADI202285835 A ECSENADI202285835 A EC SENADI202285835A EC DI202285835 A ECDI202285835 A EC DI202285835A EC SP22085835 A ECSP22085835 A EC SP22085835A
- Authority
- EC
- Ecuador
- Prior art keywords
- cancer
- treatment
- binding molecules
- fap
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a moléculas de fijación que se fijan específicamente a CD137 y FAP y su uso medicinal, composiciones farmacéuticas que las contienen y métodos para usarlas como agentes para el tratamiento y/o la prevención de cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063026883P | 2020-05-19 | 2020-05-19 | |
| US202063037241P | 2020-06-10 | 2020-06-10 | |
| PCT/US2021/032990 WO2021236658A1 (en) | 2020-05-19 | 2021-05-18 | Binding molecules for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22085835A true ECSP22085835A (es) | 2022-12-30 |
Family
ID=76502807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202285835A ECSP22085835A (es) | 2020-05-19 | 2022-11-09 | Moléculas de fijación para el tratamiento de cáncer |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12146000B2 (es) |
| EP (1) | EP4153316A1 (es) |
| JP (2) | JP2023504675A (es) |
| KR (1) | KR20230012559A (es) |
| CN (1) | CN116249555A (es) |
| AU (1) | AU2021276332A1 (es) |
| BR (1) | BR112022021447A2 (es) |
| CA (1) | CA3180665A1 (es) |
| CL (1) | CL2022003213A1 (es) |
| CO (1) | CO2022016754A2 (es) |
| CR (1) | CR20220586A (es) |
| EC (1) | ECSP22085835A (es) |
| IL (1) | IL298287A (es) |
| JO (1) | JOP20220315A1 (es) |
| MX (1) | MX2022014538A (es) |
| PE (1) | PE20230784A1 (es) |
| PH (1) | PH12022553153A1 (es) |
| TW (1) | TWI913270B (es) |
| WO (1) | WO2021236658A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023504675A (ja) | 2020-05-19 | 2023-02-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ガンの処置のための結合分子 |
| CA3184339A1 (en) * | 2020-06-10 | 2021-12-16 | Crystal Bioscience Inc. | Anti-bdnf antibodies and methods of use thereof |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗fap-light融合蛋白及其用途 |
| WO2026052000A1 (zh) * | 2024-09-04 | 2026-03-12 | 上海迈晋生物医药科技有限公司 | 包含fap/4-1bb/cd40结合分子的药物组合物及其用途 |
| CN119080935B (zh) * | 2024-10-11 | 2026-04-14 | 上海市同仁医院 | 一种抗人SMIM45-107aa单克隆抗体及其用途 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3301833A1 (de) | 1983-01-20 | 1984-07-26 | Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig | Verfahren zur simultanen synthese mehrerer oligonocleotide an fester phase |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU2782292A (en) | 1991-09-18 | 1993-04-27 | Sloan-Kettering Institute For Cancer Research | Activated stromal fibroblast-specific antibody, f19 and methods of using the same |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| IL129138A0 (en) | 1996-10-11 | 2000-02-17 | Bristol Myers Squibb Co | Methods and compositions for immunomodulation |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6323322B1 (en) | 1997-04-30 | 2001-11-27 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| CA2401252A1 (en) | 2000-03-17 | 2001-09-20 | Boehringer Ingelheim Pharma Kg | Human and humanized fap-alpha-specific antibodies |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| EP1361892A4 (en) | 2001-01-17 | 2004-10-13 | Trubion Pharmaceuticals Inc | BINDING DOMAIN FUSION PROTEIN Immunoglobulin |
| PE20021080A1 (es) | 2001-04-12 | 2003-02-12 | Boehringer Ingelheim Int | Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer |
| EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| JP5087274B2 (ja) | 2003-06-30 | 2012-12-05 | ドマンティス リミテッド | ポリペプチド |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| CN101287764B (zh) | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US8507656B2 (en) | 2008-01-28 | 2013-08-13 | Medimmune Limited | Stabilized angiopoietin-2 antibodies and uses thereof |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
| US10265357B2 (en) | 2008-10-08 | 2019-04-23 | Viratherapeutics Gmbh | Compositions, methods and uses for treating solid tumors using LCMV-GP-VSV pseudotype vectors |
| DE102008050860A1 (de) | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| EP2464220A4 (en) | 2009-08-13 | 2014-05-07 | Crystal Bioscience Inc | Transgenic animal for the production of antibodies with minimal complementarity-determining regions |
| WO2011040972A1 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| JP5950824B2 (ja) | 2009-12-07 | 2016-07-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗腫瘍抗体療法を増強するための方法 |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| EP3514169B1 (en) | 2010-11-26 | 2024-03-06 | Molecular Partners AG | Designed repeat proteins binding to serum albumin |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| JP2015501025A (ja) | 2011-10-05 | 2015-01-08 | オプテオン コーポレーション | 動的環境を監視及び/又は制御するための方法、装置、及びシステム |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| US10899840B2 (en) | 2014-02-04 | 2021-01-26 | Pfizer Inc. | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| US9494125B2 (en) | 2014-06-13 | 2016-11-15 | Innova Electronics, Inc. | System and method of ignition coil testing |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| EP3240908A2 (en) | 2014-12-30 | 2017-11-08 | F. Hoffmann-La Roche AG | Methods and compositions for prognosis and treatment of cancers |
| US20170369592A1 (en) | 2015-01-09 | 2017-12-28 | Mabimmune Diagostics AG | Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof |
| TW201632559A (zh) | 2015-02-22 | 2016-09-16 | 索倫多醫療公司 | 結合cd137之抗體治療劑 |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| BR112017024770A2 (pt) | 2015-05-21 | 2018-07-31 | Alligator Bioscience Ab | polipeptídeos inovadores |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| MY206406A (en) | 2015-10-02 | 2024-12-16 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| PE20181349A1 (es) | 2015-10-07 | 2018-08-22 | Hoffmann La Roche | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador |
| GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| JP6384461B2 (ja) | 2015-12-03 | 2018-09-05 | 株式会社デンソー | リリーフ弁装置、及び、それを用いる高圧ポンプ |
| US10392442B2 (en) | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| DE102016000353A1 (de) | 2016-01-14 | 2017-07-20 | Liebherr-Components Biberach Gmbh | Kran-, Baumaschinen- oder Flurförderzeug-Simulator |
| WO2017130076A1 (en) | 2016-01-25 | 2017-08-03 | Pfizer Inc. | Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer |
| BR112018071612A2 (pt) | 2016-04-22 | 2019-02-19 | Alligator Bioscience Ab | polipeptídeos biespecíficos inovadores contra cd137 |
| EP3243836A1 (en) | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
| KR20190014525A (ko) | 2016-05-27 | 2019-02-12 | 애브비 바이오테라퓨틱스 인크. | 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질 |
| CA3026151A1 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| US10360201B2 (en) | 2016-07-11 | 2019-07-23 | Investcloud Inc | Data exchange common interface configuration |
| KR20190057345A (ko) | 2016-09-21 | 2019-05-28 | 아말 테라퓨틱스 에스에이 | 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체 |
| CA3036564A1 (en) | 2016-09-23 | 2018-03-29 | Elstar Therapeutics, Inc. | Multispecific antibody molecules comprising lambda and kappa light chains |
| US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| EP3539080B1 (en) | 2016-11-10 | 2022-03-23 | F. Hoffmann-La Roche AG | Distance-based tumor classification |
| GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| CA3047070A1 (en) | 2017-01-03 | 2018-07-12 | F.Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| US10174122B2 (en) | 2017-01-06 | 2019-01-08 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
| GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
| SG11201906319XA (en) | 2017-01-20 | 2019-08-27 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd137+ cells |
| US10123435B2 (en) | 2017-02-02 | 2018-11-06 | Lg Electronics Inc. | Display control module and display device including the same |
| PT3443010T (pt) | 2017-02-17 | 2024-10-21 | Ose Immunotherapeutics | Novos anticorpos anti-sirpa e suas aplicações terapêuticas |
| BR112019017241A2 (pt) | 2017-04-13 | 2020-04-14 | Agenus Inc. | anticorpos anti-cd137 e métodos de uso dos mesmos |
| SG10201913147WA (en) | 2017-07-11 | 2020-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
| EP3658589B1 (en) | 2017-07-26 | 2023-09-27 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| EP3470426A1 (en) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
| EP3470428A1 (en) | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Antibodies targeting cd137 and methods of use thereof |
| US12202911B2 (en) | 2017-10-10 | 2025-01-21 | Numab Therapeutics AG | Multispecific antibody comprising CD137 binding domain and PDL1 binding domain |
| CN111183159B (zh) | 2017-10-10 | 2024-09-03 | 努玛治疗有限公司 | 靶向cd137的抗体及其使用方法 |
| PE20210844A1 (es) * | 2017-11-01 | 2021-05-10 | Hoffmann La Roche | Contorsbodies 2 + biespecificos |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| US20210015866A1 (en) | 2018-03-23 | 2021-01-21 | La Jolla Institute For Allergy And Immunology | Tissue resident memory cell profiles, and uses thereof |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| SG11202102851XA (en) | 2018-09-27 | 2021-04-29 | Celgene Corp | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF |
| TW202600150A (zh) | 2019-01-25 | 2026-01-01 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
| TWI878355B (zh) | 2019-10-02 | 2025-04-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
| JP2023504675A (ja) | 2020-05-19 | 2023-02-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ガンの処置のための結合分子 |
-
2021
- 2021-05-18 JP JP2022533221A patent/JP2023504675A/ja active Pending
- 2021-05-18 CA CA3180665A patent/CA3180665A1/en active Pending
- 2021-05-18 CR CR20220586A patent/CR20220586A/es unknown
- 2021-05-18 BR BR112022021447A patent/BR112022021447A2/pt unknown
- 2021-05-18 KR KR1020227044045A patent/KR20230012559A/ko active Pending
- 2021-05-18 CN CN202180035724.8A patent/CN116249555A/zh active Pending
- 2021-05-18 AU AU2021276332A patent/AU2021276332A1/en active Pending
- 2021-05-18 US US17/323,844 patent/US12146000B2/en active Active
- 2021-05-18 EP EP21733260.0A patent/EP4153316A1/en active Pending
- 2021-05-18 PE PE2022002692A patent/PE20230784A1/es unknown
- 2021-05-18 PH PH1/2022/553153A patent/PH12022553153A1/en unknown
- 2021-05-18 TW TW110117908A patent/TWI913270B/zh active
- 2021-05-18 MX MX2022014538A patent/MX2022014538A/es unknown
- 2021-05-18 WO PCT/US2021/032990 patent/WO2021236658A1/en not_active Ceased
- 2021-05-18 IL IL298287A patent/IL298287A/en unknown
-
2022
- 2022-11-09 EC ECSENADI202285835A patent/ECSP22085835A/es unknown
- 2022-11-17 JO JOJO/P/2022/0315A patent/JOP20220315A1/ar unknown
- 2022-11-17 CL CL2022003213A patent/CL2022003213A1/es unknown
- 2022-11-22 CO CONC2022/0016754A patent/CO2022016754A2/es unknown
-
2024
- 2024-02-09 JP JP2024018456A patent/JP2024054284A/ja active Pending
- 2024-10-02 US US18/904,482 patent/US20250136720A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230012559A (ko) | 2023-01-26 |
| MX2022014538A (es) | 2022-12-15 |
| JOP20220315A1 (ar) | 2022-11-17 |
| TWI913270B (zh) | 2026-02-01 |
| CR20220586A (es) | 2023-01-09 |
| JP2024054284A (ja) | 2024-04-16 |
| CA3180665A1 (en) | 2021-11-25 |
| US20250136720A1 (en) | 2025-05-01 |
| AU2021276332A1 (en) | 2022-11-17 |
| IL298287A (en) | 2023-01-01 |
| PE20230784A1 (es) | 2023-05-11 |
| WO2021236658A1 (en) | 2021-11-25 |
| PH12022553153A1 (en) | 2024-02-26 |
| TW202214303A (zh) | 2022-04-16 |
| BR112022021447A2 (pt) | 2022-12-13 |
| JP2023504675A (ja) | 2023-02-06 |
| US20210363273A1 (en) | 2021-11-25 |
| CO2022016754A2 (es) | 2022-11-29 |
| US12146000B2 (en) | 2024-11-19 |
| CL2022003213A1 (es) | 2023-06-30 |
| EP4153316A1 (en) | 2023-03-29 |
| CN116249555A (zh) | 2023-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022016754A2 (es) | Moléculas de fijación para el tratamiento de cáncer | |
| CL2024003895A1 (es) | Proteínas que se unen a nkg2d, flt3 y cd16; composición farmacéutica; y su uso. | |
| ECSP22083174A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| BR112023021068A2 (pt) | Compostos, composições e métodos para tratar câncer | |
| CO2021003036A2 (es) | Compuestos de anillo fusionado | |
| BR112022021884A2 (pt) | Proteínas que se ligam a nkg2d, cd16 e clec12a | |
| CY1125025T1 (el) | 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης | |
| CY1121120T1 (el) | Αρυλ- ή ετεροαρυλ-υποκατεστημενες ενωσεις βενζολιου | |
| BR112022002442A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BRPI0809164B8 (pt) | Composição para administração tópica e composição farmacêutica compreendendo a referida composição | |
| CO2022016899A2 (es) | Moduladores de il-17a | |
| CO2019006320A2 (es) | Moléculas biespecíficas de unión al receptor 2 del ligando inductor de apoptosis relacionado con tnf y anti-cadherina 17 para el tratamiento del cáncer | |
| MX383164B (es) | Composicion que contiene arn para tratamiento de enfermedades tumorales. | |
| BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
| BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| CO2022018636A2 (es) | Moduladores de il-17a | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| MX2021004566A (es) | Compuestos terapeuticos. | |
| CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
| MX2022013396A (es) | Compuestos de tetrahidroisoquinolina como activadores de nrf2. | |
| MX2024008450A (es) | Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| MX2022013398A (es) | Compuestos de tetrahidroisoquinolina como activadores de nrf2. |